Jason M Broderick

Stivarga was granted a priority review by the FDA to treat certain patients with liver cancer in the second line setting.

Adding Xtandi to Zytiga and prednisone did not improve progression-free survival for patients with metastatic castration-resistant prostate cancer, according to a recent study.

The PD-L1 inhibitor durvalumab was granted a priority review for the treatment of some patients with urothelial carcinoma.

Several trials testing vadastuximab talirine for use in patients with AML were recently halted, according to the drug's manufacturer.

The FDA approved Rubraca for patients with advanced ovarian cancer who already had two or more lines of therapy.

Adding veliparib to a chemotherapy regimen increased response rates for patients with BRCA-positive breast cancer.

Keytruda was granted a priority review to a supplemental biologics license application (sBLA) to treat a subset of patients with classical Hodgkin lymphoma.

Keytruda may be a viable treatment option for patients with advanced microsatellite instability-high cancer in the future.

The FDA approved a Darzalex (daratumumab) triplet for the treatment of relapsed myeloma.

Cabometyx was proved to be superior to Sutent, reducing rates of disease progression or death for patients with metastatic RCC, according to a recent trial.

Thanks to recent clinical trials and FDA approvals, the treatment paradigm for multiple myeloma continues to shift.

Midostaurin was granted a priority review for a new drug application by the FDA to treat a subset of patients with acute myeloid leukemia.

Opdivo was approved for patients with metastatic or recurrent squamous cell carcinoma of the head and neck.

The FDA granted ribociclib a priority review to a new drug application for certain patients with breast cancer.

The FDA granted brigatinib a priority review for the treatment of certain patients with non-small cell lung cancer.

Updated trial data shows that Opdivo had a high objective response rate for a cohort of patients with classical Hodgkin Lymphoma.

The FDA approved Keytruda to treat metastatic non-small cell lung cancer in the frontline setting.

Tecentriq was approved by the U.S. Food and Drug Administration (FDA) for some patients with lung cancer.

Yervoy reduced risk of death for patients with high-risk stage 3 melanoma in a recent study.

In a recent phase 2 trial, Cabometyx showed longer progression-free survival than Sutent in patients with metastatic kidney cancer.

The FDA granted Alecensa a breakthrough therapy designation to be used in the frontline setting for some patients with non small-cell lung cancer.

The FDA voted against approving Qapzola for treatment of some patients with bladder cancer.

The novel agent rucaparib was granted a priority review for the treatment of patients with BRCA-positive advanced ovarian cancer who have received at least two prior lines of chemotherapy.

There are now more personalized treatment options for patients with CLL.

The FDA granted Keytruda a priority review for the first-line treatment of some patients with NSCLC.

According to recent findings from a phase 3 trial, the immunotherapy Tecentriq (atezolizumab) improved survival compared with docetaxel in patients with advanced non–small cell lung cancer (NSCLC) following the failure of platinum-based chemotherapy.

The FDA has approved Blincyto (blinatumomab) for the treatment of pediatric and adolescent patients with Philadelphia chromosome-negative (Ph-) relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).

The addition of custirsen did not improve survival for a subset of patients with prostate cancer in a phase 3 trial.

When used in combination, Cotellic and Zelboraf showed a significant reduction in death rates for some patients with melanoma.

Patients now have one more option to combat chemotherapy-induced nausea and vomiting after the FDA approval of Sustol.